Evaluate the Safety and Immunogenicity of the 9-valent Human Papillomavirus Recombinant Vaccine (Hansenula Polymorpha) in Chinese Male Aged 9-45 Years: A Randomized, Blinded and Placebo-Controlled Phase I Study
Latest Information Update: 22 Apr 2024
At a glance
- Drugs Human papillomavirus recombinant vaccine nonavalent - Shanghai Bovax Biotechnology (Primary)
- Indications Anal cancer; Genital warts; Penile cancer
- Focus Adverse reactions
- Sponsors Shanghai Bovax Biotechnology
Most Recent Events
- 15 Apr 2024 Status changed from recruiting to completed.
- 12 Oct 2022 Status changed from not yet recruiting to recruiting.
- 19 Sep 2022 Planned initiation date changed from 1 Sep 2022 to 23 Sep 2022.